Inactive Instrument

Press Releases Summit Therapeutics plc London S.E.

Equities

GB00BN40HZ01

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024	05-01	BU
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024	04-24	BU
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors	04-11	BU
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum	04-10	BU
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	03-25	AQ
Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	03-22	BU
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024	03-14	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT	03-11	PR
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference	03-05	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT	03-03	PR
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	02-26	BU
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023	02-20	BU
Summit Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Call on February 20, 2024	02-15	AQ
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024	02-14	BU
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference	02-08	AQ
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023	02-08	AQ
Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference	02-07	BU
Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference	01-08	BU
Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	01-03	BU
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023	11-07	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Summit Therapeutics plc London S.E.

Equities

GB00BN40HZ01

Press Releases

Filters